Printer Friendly

ROBERTS PHARMACEUTICALS TO ACQUIRE MARKETED RESPIRATORY DRUG FROM SMITHKLINE BEECHAM

 ROBERTS PHARMACEUTICALS TO ACQUIRE MARKETED RESPIRATORY DRUG
 FROM SMITHKLINE BEECHAM
 EATONTOWN, N.J., July 16 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced earlier today that it has reached an agreement in principle with SmithKline Beecham Pharmaceuticals for the acquisition of an established respiratory drug line marketed in the United States under the Nucofed(R) trademark. The Nucofed line consists of four separate dosage forms including pediatric and expectorant syrups. Nucofed is indicated for symptomatic relief when both coughing and congestion are associated with upper respiratory infections and related conditions such as common cold, bronchitis, influenza and sinusitis.
 Robert A. Vukovich, chairman and CEO, stated, "Nucofed is an outstanding complement to our cough/cold product line. The combined and synergistic sales strength of Nucofed with our Cheracol(R) line will increase our penetration of this important pharmaceutical market segment."
 Specific terms of the agreement were not disclosed. However, Roberts reported that annual sales for the product lines exceeded $4 million and that the transaction is expected to be completed on a cash basis.
 Roberts Pharmaceuticals is an established pharmaceutical company specializing in prescription drug products which are marketed in ten countries. Roberts employs a work force of almost 300 employees and has operating subsidiary companies in the United States, Canada, and the United Kingdom. Roberts has seven drugs in late stage clinical development and currently markets over 50 different products for urological therapy, pain, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions. In 1991, Roberts reported record revenues of $14.2 million. Earlier this year, Roberts raised $95 million from a private placement of 4,000,000 shares of common stock with the Yamanouchi Pharmaceutical Company of Japan. Yamanouchi is one of the leading R&D oriented pharmaceutical companies in Japan, with a focus on the discovery and development of new chemical entity pharmaceuticals.
 -0- 7/16/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation; SmithKline Beecham
 Pharmaceuticals ST: New Jersey IN: MTC SU: TNM


GK-SS -- NY042 -- 9700 07/16/92 11:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1992
Words:340
Previous Article:FORTUNE BANCORP REPORTS THIRD QUARTER RESULTS
Next Article:TURNER SECURES CONTRACT TO BUILD P.S. 4 FOR THE NEW YORK CITY SCHOOL CONSTRUCTION AUTHORITY
Topics:


Related Articles
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF SMITHKLINE BEECHAM RESPIRATORY DRUG
SMITHKLINE BEECHAM ACQUIRES CORSODYL FROM ICI
ROBERTS PHARMACEUTICAL ACQUIRES COMHIST ANTI-ALLERGY PRESCRIPTION PHARMACEUTICAL PRODUCT LINE FROM PROCTER & GAMBLE PHARMACEUTICALS
FTC URGED TO EXAMINE VERTICAL INTEGRATION ISSUES IN PRESCRIPTION DRUG MARKET PLACE
BLOCK DRUG COMPANY TO ACQUIRE NATURE'S REMEDY(R) FROM SMITHKLINE BEECHAM CONSUMER HEALTHCARE
SMITHKLINE BEECHAM CONSUMER HEALTHCARE SELLS NATURE'S REMEDY(R) TO BLOCK DRUG COMPANY
SmithKline Beecham Makes Strategic Investment in Romania.
Proposed Merger of Glaxo Wellcome and SmithKline Beecham Creating the Global Leader in Pharmaceuticals.
SmithKline Beecham Sells Kytril to Roche, Famvir and Vectavir/Denavir to Novartis.
SmithKline Beecham to Purchase Block Drug for $1.24 Billion; Acquisition to Expand SB's Presence in Oral Healthcare And Over-the-Counter Medicines...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters